Intercept Pharmaceuticals, Inc. (ICPT)
| Market Cap | 540.83M |
| Revenue (ttm) | 345.57M |
| Net Income (ttm) | -64.72M |
| Shares Out | 29.80M |
| EPS (ttm) | -2.20 |
| PE Ratio | n/a |
| Forward PE | 7.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 453,404 |
| Open | 17.92 |
| Previous Close | 18.19 |
| Day's Range | 17.62 - 18.39 |
| 52-Week Range | 10.81 - 20.50 |
| Beta | 1.24 |
| Analysts | Buy |
| Price Target | 27.13 (+49.5%) |
| Earnings Date | Aug 3, 2022 |
About ICPT
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical... [Read more...]
Financial Performance
In 2021, ICPT's revenue was $363.47 million, an increase of 16.24% compared to the previous year's $312.69 million. Losses were -$91.43 million, -66.74% less than in 2020.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for ICPT stock is "Buy." The 12-month stock price forecast is 27.13, which is an increase of 49.48% from the latest price.
News
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Beats Revenue Estimates (Revised)
Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and +5.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)
Intercept (ICPT) posts a wider Q2 loss while sales beat estimates. The company reissues guidance.
Intercept (ICPT) Earnings and Sales Miss Estimates in Q2
Intercept (ICPT) posts a wider Q2 loss and sales miss estimates. The company reissues guidance.
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Misses Revenue Estimates
Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and 24.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022
MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...
Needham Cuts Price Target On This NASH-Focused Stock As Its Awaits Visibility On Regulatory Path
Yesterday, Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced data from the new interim analysis of the Phase 3 REGENERATE trial evaluating obeticholic acid in nonalcoholic steatohepatitis (NASH). N...
Intercept (ICPT) Reports Positive Data From NASH Study on OCA
Intercept (ICPT) reports positive top-line results from a new analysis of its ongoing pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
Intercept (ICPT) Ocaliva Drives Growth, Pipeline Setbacks Hurt
Intercept (ICPT) currently has only one marketed product in its portfolio, Ocaliva, for treating PBC. The company continues to evaluate the potential of OCA in treating progressive liver diseases.
Why Did Intercept Pharmaceuticals (ICPT) Stock Fall 10% Today?
A fresh press release from Intercept Pharmaceuticals reveals positive data from an important clinical trial. Yet, ICPT stock is dropping.
Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Ou...
MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to t...
Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022
MORRISTOWN, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to t...
Intercept (ICPT) Announces Delay in Meeting With the FDA
Intercept (ICPT) faces yet another setback as its resubmission for NDA for OCA for NASH gets delayed.
Regulatory Update On Intercept Pharma's Obeticholic Acid For NASH Delayed Again
Intercept Pharmaceuticals Inc's (NASDAQ: ICPT) pre-submission meeting to discuss the marketing application for obeticholic acid (OCA) in NASH has been moved to July (vs. June scheduling).
Intercept set to meet with FDA in July about NASH drug
Shares of Intercept Pharmaceuticals Inc. ICPT, -9.77% were up 2.2% in premarket trading on Monday after the company said a meeting with the Food and Drug Administration to discuss resubmitting an applic...
Intercept Provides Update on NASH Regulatory Timeline
MORRISTOWN, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to t...
Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC
COBALT study in advanced PBC, previously terminated early due to feasibility challenges, did not demonstrate a statistically significant difference in clinical endpoints between Ocaliva ® and placebo
Intercept (ICPT) Q1 Earnings Top, Ocaliva Sales Miss Estimates
Intercept (ICPT) posts a narrower-than-expected loss in the first quarter. Sales lag estimates.
Here is why Intercept is up 30%
Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) shares are up 30% after announcing an agreement to sell some of its foreign subsidiaries plus rights to its international operation, including the Ocaliva c...
Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates
Intercept (ICPT) delivered earnings and revenue surprises of 34.83% and 2.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Intercept Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Worldwide Ocaliva® net sales of $88.6 million, representing 8% growth over the prior year quarter
Why Intercept Shares Are Rising Today
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has agreed to sell certain foreign subsidiaries and rights regarding its international operations, including a license to commercialize Ocaliva (obeticholic ...
Why Is Intercept Pharmaceuticals (ICPT) Stock Up Today?
Intercept Pharmaceuticals (ICPT) stock is soaring higher on Thursday after the biopharmaceutical company revealed a deal with Advanz Pharma. The post Why Is Intercept Pharmaceuticals (ICPT) Stock Up Today?
Intercept Pharma Scores $450 Million Deal For Its Flagship Liver Drug
Intercept sold the international rights to its liver-disease treatment, Ocaliva, for up to $450 million on Thursday, and ICPT stock soared. The post Intercept Pharma Scores $450 Million Deal For Its Fla...
Intercept Announces Advanz Pharma to Acquire Ocaliva in PBC in Markets Outside the U.S. for up to $450MM, including $...
Agreement includes rights for Advanz to commercialize orphan drug Ocaliva® for PBC outside the U.S., as well as the transition to Advanz of the international commercial and medical infrastructure of Int...